Advances in SGLT2 Inhibitor Therapy: Comparative Evidence for Empagliflozin and Dapagliflozin in Cardio-Renal-Metabolic Disorders

Cardiovascular disease, Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) interact to cause the progressive multisystem condition known as cardio-renal-metabolic (CRM) syndrome. With pleiotropic advantages that go beyond glycaemic control, sodium-glucose cotransporter-2 (SGLT2) inhibitors have completely changed the way CRM is managed. To compile and contrast clinical data on dapagliflozin and empagliflozin throughout the CRM continuum's glycaemic, cardiovascular, renal, and metabolic outcomes. Pharmacokinetic studies, real-world observational cohorts, randomised cardiovascular and renal outcome trials, and regulatory guidelines were all narratively reviewed. A summary was provided of head-to-head meta-analytic data evaluating HbA1c, cardiovascular risk scores, and estimated glomerular filtration rate (eGFR). Regardless of diabetes status, both drugs showed strong, class-consistent benefits, such as decreases in heart failure hospitalisation, cardiovascular events, and CKD progression. HbA1c reduction (SMD −0.10; 95% CI −0.29 to 0.09), cardiovascular risk scores (SMD 0.11; 95% CI −0.08 to 0.31), and renal outcomes by eGFR (SMD 0.11; 95% CI −0.08 to 0.31) did not differ significantly, according to pooled head-to-head analyses. Comparable long-term risks for severe adverse cardiovascular events, acute renal injury, and the progression of chronic kidney disease were established by large real-world registries. Dapagliflozin slightly improved blood pressure and cholesterol, while empagliflozin showed better weight reduction and glycaemic control, though differences were not significant. Empagliflozin and dapagliflozin are interchangeable as a class effect because they offer comparable, clinically significant protection over the CRM spectrum. Instead of assuming molecular superiority, therapeutic selection should be based on patient phenotype and clinical priorities.